☆ 4.7 Article

Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway

PHYTOMEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Plant Sciences

Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN/PI3K/AKT pathway

Tao Wang et al.

Summary: The study aimed to investigate the mechanism by which brusatol regulates the growth of renal cancer cells through the PTEN/PI3K/AKT signaling pathway. The results showed that brusatol significantly inhibited the proliferation, migration, and invasion of A498, ACHN, and OSRC-2 renal cancer cell lines, and increased apoptosis rates.

JOURNAL OF ETHNOPHARMACOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System

Angela Lamarca et al.

Summary: This study aimed to assess the survival of intrahepatic cholangiocarcinoma with liver metastases compared to other early stages and propose a modified version of AJCC staging that includes liver metastases as a separate stage. Results showed that iCCA with liver metastases had a worse outcome compared to other early stages, suggesting the need for a modification to AJCC staging to better reflect this difference.

HEPATOLOGY (2021)

Add to Collection

Article Oncology

Long Non-coding RNA CASC15 Promotes Intrahepatic Cholangiocarcinoma Possibly through Inducing PRDX2/PI3K/AKT Axis

Yuan Zhang et al.

Summary: CASC15 is highly expressed in ICC tissues and correlated with higher TNM stage. Knockdown of CASC15 in ICC cells reduced cell proliferation, migration, invasiveness and increased apoptosis, and G1/S block. PRDX2 binds to CASC15. Knockdown of CASC15 decreased PRDX2 expression which was rescued by the inhibition of proteasome formation.

CANCER RESEARCH AND TREATMENT (2021)

Add to Collection

Article Medicine, Research & Experimental

Brusatol inhibits laryngeal cancer cell proliferation and metastasis via abrogating JAK2/STAT3 signaling mediated epithelial-mesenchymal transition

Jiangtao Zhou et al.

Summary: The study explored the role of Brusatol (BR) in human laryngeal squamous carcinoma cells (Hep-2) using in vitro and in vivo approaches. It was found that BR could inhibit the viability, migration, and invasion of Hep-2 cells without significant toxicity to normal cells. Mechanistically, BR induced cell apoptosis and suppressed cell proliferation by blocking cells in S phase. Additionally, BR was shown to inhibit the protein expression levels of epithelial-mesenchymal transition (EMT) related markers.

LIFE SCIENCES (2021)

Add to Collection

Review Gastroenterology & Hepatology

Systemic therapies for intrahepatic cholangiocarcinoma

Robin Kate Kelley et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways

Pei Tiemin et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Oncology

Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway

Songbin Guo et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Brusatol suppresses STAT3-driven metastasis by downregulating epithelial-mesenchymal transition in hepatocellular carcinoma

Jong Hyun Lee et al.

JOURNAL OF ADVANCED RESEARCH (2020)

Add to Collection

Article Cell Biology

Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma

Fei Song et al.

CELL DEATH & DISEASE (2020)

Add to Collection

Review Gastroenterology & Hepatology

Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances

Alphonse E. Sirica et al.

HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

Paola Bertuccio et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Oncology

The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma

Georg Lurje et al.

EJSO (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Brusatol, an NRF2 inhibitor for future cancer therapeutic

Sabrina J. Cai et al.

CELL AND BIOSCIENCE (2019)

Add to Collection

Review Cell Biology

EMT Transition States during Tumor Progression and Metastasis

Ievgenia Pastushenko et al.

TRENDS IN CELL BIOLOGY (2019)

Add to Collection

Review Oncology

Cholangiocarcinoma - evolving concepts and therapeutic strategies

Sumera Rizvi et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, Research & Experimental

Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma

Ruifan Ye et al.

BIOMEDICINE & PHARMACOTHERAPY (2018)

Add to Collection

Article Cell Biology

Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway

Yukai Xiang et al.

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2018)

Add to Collection

Article Oncology

Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling

Rui Peng et al.

CANCER MEDICINE (2018)

Add to Collection

Review Oncology

EMT in cancer

Thomas Brabletz et al.

NATURE REVIEWS CANCER (2018)

Add to Collection

Article Medicine, Research & Experimental

Osthole induces apoptosis and suppresses proliferation via the PI3K/Akt pathway in intrahepatic cholangiocarcinoma

Xingyang Zhu et al.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)

Add to Collection

Article Gastroenterology & Hepatology

LncRNA-CCAT1 Promotes Migration, Invasion, and EMT in Intrahepatic Cholangiocarcinoma Through Suppressing miR-152

Shouhua Zhang et al.

DIGESTIVE DISEASES AND SCIENCES (2017)

Add to Collection

Review Gastroenterology & Hepatology

Clinical diagnosis and staging of cholangiocarcinoma

Boris Blechacz et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)

Add to Collection

Article Surgery

Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma

WR Jarnagin et al.

ANNALS OF SURGERY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.